Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

822
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Cancer02:18

Cancer

51.7K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment-A report from ICTHIC 2021.

Research and practice in thrombosis and haemostasis·2022
Same author

Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study.

Blood advances·2021
Same author

Vascular Imaging in the Asymptomatic High-risk Cancer Population: A Role for Thrombosis Screening and Therapy Management.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine·2021
Same author

American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

Blood advances·2019
Same author

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2019
Same author

PGM Guidelines for Description of Criteria and Methods for Testing of Specificity of Assay Methods for Quantities in the Fibrinolytic System.

EJIFCC·2019
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.2K

Cancer-associated thrombosis.

Gregory C Connolly1, Charles W Francis

  • 11James P. Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester, NY.

Hematology. American Society of Hematology. Education Program
|December 10, 2013
PubMed
Summary
This summary is machine-generated.

Cancer-associated thrombosis is a major cause of death and complications in cancer patients. This review covers risk assessment using models like Khorana, and discusses prophylaxis and treatment strategies for venous thromboembolism (VTE).

More Related Videos

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

8.2K
Three-dimensional Co-culture Model for Tumor-stromal Interaction
08:39

Three-dimensional Co-culture Model for Tumor-stromal Interaction

Published on: February 2, 2015

16.8K

Related Experiment Videos

Last Updated: May 5, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.2K
Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

8.2K
Three-dimensional Co-culture Model for Tumor-stromal Interaction
08:39

Three-dimensional Co-culture Model for Tumor-stromal Interaction

Published on: February 2, 2015

16.8K

Area of Science:

  • Oncology
  • Hematology
  • Medical Thrombosis

Background:

  • Cancer-associated thrombosis is a significant cause of morbidity and mortality, accounting for nearly 20% of all venous thromboembolism (VTE) cases.
  • Understanding risk factors and improving prediction models are crucial for managing VTE in cancer patients.
  • Existing research has expanded the knowledge of risk factors, leading to the development of clinical prediction models.

Purpose of the Study:

  • To review recent clinical trials on the prophylaxis and treatment of VTE in cancer patients.
  • To present consensus guidelines and expert opinions on managing VTE in challenging clinical scenarios.
  • To highlight the importance of risk stratification tools like the Khorana Risk Model.

Main Methods:

  • Review of recent clinical trials concerning VTE prophylaxis and treatment in oncology.
  • Analysis of validated clinical prediction models for identifying high-risk cancer patients.
  • Compilation of consensus guidelines and expert opinions for VTE management.

Main Results:

  • The Khorana Risk Model, utilizing accessible clinical factors and biomarkers, has demonstrated validation in multiple studies for predicting VTE risk.
  • Recent trials provide updated evidence on the efficacy of various prophylaxis and treatment strategies for VTE in cancer.
  • Established guidelines offer expert recommendations for managing complex VTE cases in cancer patients.

Conclusions:

  • Accurate risk assessment using validated models like Khorana is essential for proactive VTE management in cancer care.
  • Evidence-based prophylaxis and treatment strategies, guided by recent clinical trials and expert consensus, are critical for improving outcomes.
  • Effective management of cancer-associated thrombosis requires a comprehensive approach integrating risk prediction, evidence-based interventions, and expert clinical judgment.